Bicocca Open Archive

Logo unimib boa
CORTESI, PAOLO ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.610
AS - Asia 12.570
EU - Europa 8.869
SA - Sud America 1.778
AF - Africa 336
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 13
Totale 40.232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.132
SG - Singapore 4.793
CN - Cina 2.379
IT - Italia 2.325
HK - Hong Kong 1.686
VN - Vietnam 1.674
BR - Brasile 1.328
RU - Federazione Russa 1.303
DE - Germania 1.150
SE - Svezia 709
IE - Irlanda 681
FR - Francia 575
GB - Regno Unito 488
IN - India 427
UA - Ucraina 414
CA - Canada 292
FI - Finlandia 280
ID - Indonesia 225
BD - Bangladesh 207
TR - Turchia 180
NL - Olanda 173
AR - Argentina 171
KR - Corea 156
DK - Danimarca 153
AT - Austria 146
IQ - Iraq 128
MX - Messico 120
ZA - Sudafrica 105
ES - Italia 99
PK - Pakistan 95
PH - Filippine 77
JP - Giappone 76
SA - Arabia Saudita 72
PL - Polonia 67
EC - Ecuador 66
CH - Svizzera 62
BE - Belgio 51
VE - Venezuela 51
IR - Iran 50
UZ - Uzbekistan 48
CO - Colombia 47
AU - Australia 46
CL - Cile 44
MA - Marocco 40
AE - Emirati Arabi Uniti 33
EG - Egitto 32
KE - Kenya 32
TH - Thailandia 32
MY - Malesia 30
ET - Etiopia 28
TN - Tunisia 25
CZ - Repubblica Ceca 24
JO - Giordania 24
NP - Nepal 23
PT - Portogallo 23
PY - Paraguay 22
RO - Romania 22
PE - Perù 20
TW - Taiwan 20
DZ - Algeria 19
BG - Bulgaria 17
AL - Albania 16
BO - Bolivia 15
IL - Israele 15
LT - Lituania 15
JM - Giamaica 13
KG - Kirghizistan 13
OM - Oman 13
DO - Repubblica Dominicana 12
LB - Libano 12
AZ - Azerbaigian 11
EU - Europa 11
GR - Grecia 11
NO - Norvegia 11
LK - Sri Lanka 10
UY - Uruguay 10
CR - Costa Rica 9
NG - Nigeria 9
KZ - Kazakistan 8
MD - Moldavia 8
RS - Serbia 8
BH - Bahrain 7
GT - Guatemala 7
MN - Mongolia 7
NZ - Nuova Zelanda 7
SI - Slovenia 7
BY - Bielorussia 6
HU - Ungheria 6
KW - Kuwait 6
NI - Nicaragua 6
PS - Palestinian Territory 6
SN - Senegal 6
GA - Gabon 5
GE - Georgia 4
GH - Ghana 4
HN - Honduras 4
LU - Lussemburgo 4
QA - Qatar 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
Totale 40.150
Salva come PNG Salva come JPEG
Città #
Singapore 2.356
Ann Arbor 1.847
Hong Kong 1.658
Ashburn 1.491
San Jose 1.207
Fairfield 858
Woodbridge 833
Chandler 728
Houston 699
Frankfurt am Main 658
Dublin 654
Milan 616
Wilmington 566
Ho Chi Minh City 506
New York 493
Santa Clara 437
Hanoi 417
Seattle 388
Jacksonville 387
Dearborn 345
Beijing 326
Dallas 301
The Dalles 297
Los Angeles 296
Chicago 289
Cambridge 280
Princeton 278
Hefei 251
Council Bluffs 213
Lauterbourg 171
Jakarta 159
Helsinki 148
Nanjing 146
Seoul 132
São Paulo 132
Altamura 128
Lawrence 124
Buffalo 118
Rome 116
Boardman 112
Moscow 110
Vienna 107
Shanghai 101
Orem 99
Munich 91
Guangzhou 78
London 78
Toronto 66
Da Nang 65
San Diego 64
Tokyo 61
Haiphong 60
Lachine 60
Nuremberg 59
Rio de Janeiro 53
Andover 51
Baghdad 50
Chennai 50
Hangzhou 48
Nanchang 48
Johannesburg 47
Warsaw 47
Lappeenranta 45
Shenyang 45
Denver 43
Dong Ket 43
Tianjin 43
Columbus 42
Phoenix 41
Zurich 40
Paris 38
Tashkent 38
Montreal 37
Amsterdam 36
Boston 36
Brooklyn 36
Ottawa 36
Mexico City 35
Mumbai 35
Poplar 35
Bologna 34
Brussels 34
Fremont 34
Jinan 34
Changsha 32
Atlanta 31
Can Tho 31
Dhaka 31
Istanbul 31
San Francisco 31
Brasília 30
Zhengzhou 30
Jiaxing 29
Verona 29
Biên Hòa 28
Hebei 28
Lahore 28
New Delhi 28
Lissone 27
Pune 27
Totale 23.965
Salva come PNG Salva come JPEG
Nome #
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 567
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 554
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 465
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 442
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 441
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 428
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023 426
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 404
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 386
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 377
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 377
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 366
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 361
Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis 357
Use of health care administrative databases to estimate the burden of breast cancer. 352
Use of health care administrative databases to estimate the burden of multiple sclerosis: a population-based study 345
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 341
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 338
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 331
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 319
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 317
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 313
Health related quality of life in chronic liver diseases 313
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 309
Costs and effectiveness of influenza vaccination: A systematic review 307
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 307
The socioeconomic burden of patients affected by hemophilia with inhibitors 301
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 300
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 297
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 289
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 289
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 289
The impact of liver disease on the health-related quality of life 285
Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 281
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 277
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 276
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 276
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 276
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 275
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 273
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 270
Time-Trends in Air Pollution Impact on Health in Italy, 1990–2019: An Analysis From the Global Burden of Disease Study 2019 269
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 269
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 267
Sustainability of the Italian National Health Service 266
Health Related Quality of Life in the Major Liver Conditions 265
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 264
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 264
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 262
Azithromycin use and outcomes in patients with COVID-19: an observational real-world study 259
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 259
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 259
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 259
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 258
Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017 257
Difference in health related quality of life of chronic liver diseases and general population 250
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 249
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 248
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 246
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 246
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 243
Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions 242
Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database 242
Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments 241
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 239
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 239
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 238
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 237
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 237
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 234
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 233
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 233
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 232
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 231
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation 231
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 229
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 229
Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products 229
Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 228
Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database 227
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 225
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 224
Preferenze della popolazione italiana per gli stati di salute dell'EQ-5D 224
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view 223
Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis 222
Economic Burden Of Stroke: Analysis From An Administrative Database 220
Incidence of inhibitors to recombinant factor VIII products – A meta-analysis of 1,852 previously untreated patients 218
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 217
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 215
Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases 215
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy 215
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 214
Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study 214
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 212
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 211
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 211
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 209
Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment 209
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 209
Italian population-based values of EQ-5D health states 206
Totale 28.020
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.264
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.264
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021416 0 0 0 0 0 0 0 0 0 0 148 268
2021/20221.868 137 182 253 178 130 146 64 121 109 129 106 313
2022/20233.149 327 896 275 271 212 452 57 195 222 49 100 93
2023/20242.714 98 119 93 149 295 645 397 119 233 114 146 306
2024/20257.707 352 716 355 366 610 469 444 293 795 929 1.013 1.365
2025/202616.555 2.107 1.037 1.194 1.799 2.071 1.059 2.630 798 1.441 1.926 493 0
Totale 41.513